Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › dermatomyositis

Dermatomyositis

Part of Polymyositis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for dermatomyositis

17 trials tracked for dermatomyositis: 8 in phase 3 or 4 and 4 with published results. The most-cited published study has 231 citations.

17Trials tracked
8Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 6 Phase 2 8 Phase 1 1
  1. Phase 3 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Completed · 231 cited
  2. Phase 3 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Completed · 201 cited
  3. Phase 3 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed · 46 cited
  4. Phase 4 Abatacept in Juvenile Dermatomyositis Completed · 28 cited
  5. Phase 4 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Completed
  6. Phase 3 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed
Show 11 more trials
  1. Phase 3 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Completed
  2. Phase 3 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Completed
  3. Phase 2 A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis Completed
  4. Phase 2 An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study Completed
  5. Phase 2 Trial of IMO-8400 in Adult Patients With Dermatomyositis Completed
  6. Phase 2 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed
  7. Phase 2 Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. Completed
  8. Phase 2 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed
  9. Phase 2 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed
  10. Phase 2 A Study In Adults With Moderate To Severe Dermatomyositis Completed
  11. Phase 1 A Pilot Study of Etanercept in Dermatomyositis Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Brepocitinib 30 mg improved Total Improvement Score versus placebo in dermatomyositis patients over 52 weeks
Drug Pipeline RCT
Brepocitinib 30 mg improved Total Improvement Score versus placebo in dermatomyositis patients over 52 weeks New Pill Eases Stubborn Muscle and Skin Disease Symptoms
This Phase 3, double-blind, randomized, placebo-controlled trial enrolled 241 adults with dermatomyositis. The once-daily oral brepocitinib …
• Brepocitinib 30 mg significantly improves muscle strength and skin rashes • Helps adults with treatment-resistant dermatomyositis regain d…
May 14, 2026
Male sex and advanced age associated with higher risk of RP-ILD in anti-MDA5 dermatomyositis patients
Allergy & Immunology Meta-analysis
Male sex and advanced age associated with higher risk of RP-ILD in anti-MDA5 dermatomyositis patients Some Patients With This Rare Lung-Muscle Disease Face Faster Decline
This systematic review and meta-analysis of 15 studies evaluated factors associated with rapidly progressive interstitial lung disease (RP-I…
Men and older adults with a rare autoimmune lung disease are at higher risk of rapid, life-threatening lung damage, a new review finds.
Frontiers Apr 16, 2026
JSLE linked to higher CVD risk factors than JDM in adults with childhood-onset autoimmune diseases
Rheumatology Cohort
JSLE linked to higher CVD risk factors than JDM in adults with childhood-onset autoimmune diseases Study compares heart health risks in adults with childhood-onset lupus or dermatomyositis
A single-centre longitudinal cohort study of 76 JSLE and 79 JDM adults found JSLE had higher hypertension, dyslipidaemia, and cholesterol le…
Adults with childhood lupus face higher heart risks like high blood pressure and cholesterol compared to those with juvenile dermatomyositis…
medRxiv Apr 13, 2026